In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Jude Onyia Biography and Net Worth

Insider of Neurocrine Biosciences

Jude Onyia, Ph.D. was appointed Chief Scientific Officer in November 2021 and leads the drug discovery and non-clinical development teams responsible for bolstering and advancing the company’s pipeline of therapeutic candidates. Additionally, in the beginning of 2023, Dr. Onyia joined Voyager Therapeutics, Inc.’s board of directors. A scientist with more than 25 years of experience in the pharmaceutical industry, Dr. Onyia is the former Vice President of Biotechnology Discovery Research at Eli Lilly and Company. At Lilly, Dr. Onyia contributed to the discovery and/or advancement of more than 60 clinical candidates across multiple therapeutic areas, which led to seven approved medicines. He also was responsible for more than 50 pre-candidate programs across multiple therapeutic areas. Dr. Onyia holds a B.S. in Forest Biology from the State University of New York (SUNY) College of Environmental Science and Forestry, as well as a Ph.D. in Cell and Molecular Biology from the SUNY Health Science Center, both at Syracuse, NY.

What is Jude Onyia's net worth?: The estimated net worth of Jude Onyia is at least $1.47 million as of November 29th, 2023. Dr. Onyia owns 11,732 shares of Neurocrine Biosciences stock worth more than $1,474,126 as of November 22nd. This net worth evaluation does not reflect any other assets that Dr. Onyia may own. Additionally, Dr. Onyia receives an annual salary of $1,220,000.00 as Insider at Neurocrine Biosciences. Learn More about Jude Onyia's net worth.
How old is Jude Onyia?: Dr. Onyia is currently 60 years old. There are 7 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Jude Onyia's age.
What is Jude Onyia's salary?: As the Insider of Neurocrine Biosciences, Inc., Dr. Onyia earns $1,220,000.00 per year. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $2,050,000.00 per year. Learn More on Jude Onyia's salary.
How do I contact Jude Onyia?: The corporate mailing address for Dr. Onyia and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Jude Onyia's contact information.
Has Jude Onyia been buying or selling shares of Neurocrine Biosciences?: Jude Onyia has not been actively trading shares of Neurocrine Biosciences during the past quarter. Most recently, Jude Onyia sold 2,331 shares of the business's stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $113.57, for a transaction totalling $264,731.67. Following the completion of the sale, the insider now directly owns 11,732 shares of the company's stock, valued at $1,332,403.24. Learn More on Jude Onyia's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 48 times. They sold a total of 592,855 shares worth more than $80,092,533.10. The most recent insider tranaction occured on August, 15th when Director William H Rastetter sold 14,250 shares worth more than $2,090,332.50. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 8/15/2024.

Jude Onyia Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/29/2023	Sell	2,331	$113.57	$264,731.67	11,732
8/21/2023	Sell	3,198	$107.37	$343,369.26	9,638

Jude Onyia Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $125.65

$124.38

$127.00

50 Day Range

MA: $118.55

$111.62

$127.17

2 Week Range

Now: $125.65

$110.52

$157.98

Volume

1,206,275 shs

Average Volume

874,442 shs

Market Capitalization

$12.72 billion

P/E Ratio

33.69

Dividend Yield

N/A

Beta

0.35

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Jude Onyia Biography and Net Worth

What is Jude Onyia's net worth?

How old is Jude Onyia?

What is Jude Onyia's salary?

How do I contact Jude Onyia?

Has Jude Onyia been buying or selling shares of Neurocrine Biosciences?

Who are Neurocrine Biosciences' active insiders?

Are insiders buying or selling shares of Neurocrine Biosciences?